Antengene has received approval in Australia to initiate a Phase I clinical study of ATG-201, its investigational CD19/CD3 bispecific T-cell engager for B cell-related autoimmune diseases.
The ATTRACT study has received approval from an Australian Human Research Ethics Committee and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.
ATG-201 is a proprietary CD19-targeting bispecific T-cell engager designed to eliminate CD19-expressing B cells.
The candidate incorporates a steric-hindrance masking technology intended to regulate T-cell-engager activity and potentially improve the therapeutic profile of treatment.
B-cell depletion has emerged as an important therapeutic approach across several autoimmune diseases, with interest growing in therapies capable of producing deeper immune-system resetting.
The clinical study will provide initial information on ATG-201's safety, tolerability, pharmacokinetics and biological activity in patients with B cell-related autoimmune conditions.
Antengene has been expanding its research activities beyond oncology into autoimmune disease, applying its antibody and T-cell-engager platforms to disorders driven by pathogenic B cells.
The Australian approval allows the company to begin clinical evaluation of ATG-201 as part of this broader strategy.
The programme also represents continued expansion of next-generation bispecific antibody approaches beyond cancer, where T-cell engagers have been most extensively developed.
Data from the ATTRACT study will help determine the candidate's subsequent clinical development strategy and potential applicability across multiple autoimmune indications.
